Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Faith L Henderson"'
Autor:
Tebogo M Segolodi, Faith L Henderson, Charles E Rose, Kyle T Turner, Clement Zeh, Peter N Fonjungo, Richard Niska, Clyde Hart, Lynn A Paxton
Publikováno v:
PLoS ONE, Vol 9, Iss 4, p e93034 (2014)
IntroductionAccurate clinical laboratory reference values derived from a local or regional population base are required to correctly interpret laboratory results. In Botswana, most reference intervals used to date are not standardized across clinical
Externí odkaz:
https://doaj.org/article/8e3e2ce4a42a48a39f8d8f3214af8674
Autor:
Michael Kasonde, Richard W Niska, Charles Rose, Faith L Henderson, Tebogo M Segolodi, Kyle Turner, Dawn K Smith, Michael C Thigpen, Lynn A Paxton
Publikováno v:
PLoS ONE, Vol 9, Iss 3, p e90111 (2014)
Tenofovir-emtricitabine (TDF-FTC) pre-exposure prophylaxis (PrEP) has been found to be effective for prevention of HIV infection in several clinical trials. Two studies of TDF PrEP among men who have sex with men showed slight bone mineral density (B
Externí odkaz:
https://doaj.org/article/33ab052d56ba4978b007732c7a75b336
Autor:
Felicia P. Hardnett, Peter H. Kilmarx, Lebogang Makgekgenene, Tebogo M. Segolodi, Deborah A. Gust, Charles K. Malotte, Lynn A. Paxton, Charles E. Rose, Faith L. Henderson, Fatma A. Soud, Poloko Kebaabetswe
Publikováno v:
JAIDS Journal of Acquired Immune Deficiency Syndromes. 73:556-563
OBJECTIVE Among participants of a clinical trial to test the efficacy of tenofovir/emtricitabine in protecting heterosexual men and women living in Botswana from HIV infection, the aim was to determine (1) if sexual risk behavior, specifically condom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36674f3b9622591cf35ca0d13e612915
https://doi.org/10.1097/qai.0000000000001143
https://doi.org/10.1097/qai.0000000000001143
Publikováno v:
World journal of AIDS
Recent clinical trials have shown that a daily dose of oral TDF/FTC pre-exposure prophylaxis (PrEP) is effective in reducing human immunodeficiency (HIV) risk. Understanding trial participants’ perspectives about retention and PrEP adherence is cri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f3b25f1716db265bd07837dcc47ce62
http://europepmc.org/articles/PMC4708891
http://europepmc.org/articles/PMC4708891
Autor:
Charles E. Rose, Tebogo M. Segolodi, Lovemore Ian Chirwa, Faith L. Henderson, Fatma A. Soud, Kata Chillag, Jeffrey A. Johnson, Michael Kasonde, Lynn A. Paxton, Roman Gvetadze, John T. Brooks, Daniel Abebe, Craig W. Hendrix, Poloko Kebaabetswe, Sandra H. Johnson, Dawn K. Smith, C. Kevin Malotte, Thom Sukalac, Michael C. Thigpen, Rodreck Mutanhaurwa, Vasavi Thomas, Clyde E. Hart, Evans Buliva, Sonal R Pathak
Publikováno v:
New England Journal of Medicine. 367:423-434
A B S T R AC T Background Preexposure prophylaxis with antiretroviral agents has been shown to reduce the transmission of human immunodeficiency virus (HIV) among men who have sex with men; however, the efficacy among heterosexuals is uncertain. Meth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5a089707cd0a46a87f94afa17ced9421
https://doi.org/10.1056/nejmoa1110711
https://doi.org/10.1056/nejmoa1110711
Autor:
Michael J. Stirratt, Charles E. Rose, Poloko Kebaabetswe, Lynn A. Paxton, Simone C. Gray, Eleanor McLellan-Lemal, Faith L. Henderson, Tiffany Williams
Publikováno v:
AIDS and behavior. 19(5)
This study examined study product adherence and its determinants in the Botswana oral pre-exposure prophylaxis efficacy trial. Among the 1,219 participants, the mean adherence by pill count and 3-day self-report was 94 % for each. In multivariable mo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ab9ce65071dd641437b7f959b317345
https://pubmed.ncbi.nlm.nih.gov/25186785
https://pubmed.ncbi.nlm.nih.gov/25186785
Autor:
Charles E. Rose, Kyle Turner, Tebogo M. Segolodi, Dawn K. Smith, Richard W. Niska, Faith L. Henderson, Lynn A. Paxton, Michael Kasonde, Michael C. Thigpen
Publikováno v:
PLoS ONE, Vol 9, Iss 3, p e90111 (2014)
PLoS ONE
PLoS ONE
Background Tenofovir-emtricitabine (TDF-FTC) pre-exposure prophylaxis (PrEP) has been found to be effective for prevention of HIV infection in several clinical trials. Two studies of TDF PrEP among men who have sex with men showed slight bone mineral
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c67b521b638c3dc28ebc49ca012c5823
http://europepmc.org/articles/PMC3953113?pdf=render
http://europepmc.org/articles/PMC3953113?pdf=render